Published in JAMA Intern Med on January 01, 2016
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA (2016) 2.23
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. J Int AIDS Soc (2017) 1.06
Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc (2016) 1.04
Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting. PLoS One (2016) 0.97
Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States. J Infect Dis (2016) 0.96
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal (2016) 0.90
Healthcare Access and PrEP Continuation in San Francisco and Miami Following the U.S. PrEP Demo Project. J Acquir Immune Defic Syndr (2016) 0.89
Implementation of Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention Among Men Who Have Sex With Men at a New England Sexually Transmitted Diseases Clinic. Sex Transm Dis (2016) 0.86
Changes in Familiarity with and Willingness to Take Preexposure Prophylaxis in a Longitudinal Study of Highly Sexually Active Gay and Bisexual Men. LGBT Health (2016) 0.85
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr (2017) 0.84
Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. AIDS Res Hum Retroviruses (2016) 0.83
Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr (2016) 0.82
Optimizing Delivery of Preexposure Prophylaxis-The Next Frontier. JAMA Intern Med (2016) 0.82
Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men. AIDS Behav (2016) 0.81
Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS One (2017) 0.81
Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol. BMC Infect Dis (2017) 0.80
Sexually transmitted infections and pre-exposure prophylaxis: challenges and opportunities among men who have sex with men in the US. AIDS Res Ther (2016) 0.79
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. J Acquir Immune Defic Syndr (2016) 0.79
"Support Your Client at the Space That They're in": HIV Pre-Exposure Prophylaxis (PrEP) Prescribers' Perspectives on PrEP-Related Risk Compensation. AIDS Patient Care STDS (2017) 0.78
Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. BMJ Open (2016) 0.78
Individual HIV Risk versus Population Impact of Risk Compensation after HIV Preexposure Prophylaxis Initiation among Men Who Have Sex with Men. PLoS One (2017) 0.78
Antiretroviral pre-exposure prophylaxis: A new opportunity to slow HIV spread in India. Indian J Med Res (2016) 0.78
The "Safe Sex" Conundrum: Anticipated Stigma From Sexual Partners as a Barrier to PrEP Use Among Substance Using MSM Engaging in Transactional Sex. AIDS Behav (2017) 0.77
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrob Agents Chemother (2016) 0.77
Pharmacology supports on-demand PrEP. Lancet HIV (2016) 0.77
Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): Findings from a large cohort of gay and bisexual men in the U.S. Soc Sci Med (2016) 0.77
The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc (2016) 0.76
Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. Infect Dis Ther (2016) 0.76
Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. J Int AIDS Soc (2016) 0.75
Informing Strategies to Build PrEP Capacity among San Francisco Bay Area Clinicians. J Acquir Immune Defic Syndr (2016) 0.75
Preexposure Prophylaxis and Patient Centeredness: A Call for Holistically Protecting and Promoting the Health of Gay Men. Am J Mens Health (2016) 0.75
Reaching Key Populations: PrEP Uptake in an Urban Health Care System in the Bronx, New York. AIDS Behav (2016) 0.75
HIV pre-exposure prophylaxis for women. J Virus Erad (2016) 0.75
Reaching High-Risk Patients for HIV Preexposure Prophylaxis. JAMA (2016) 0.75
Medication Sharing is Rare among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention. J Acquir Immune Defic Syndr (2017) 0.75
Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection. J Infect Dis (2016) 0.75
Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care. J Gen Intern Med (2016) 0.75
Top Questions in ID: Pre-exposure Prophylaxis for HIV. Open Forum Infect Dis (2017) 0.75
Self-reported race and ethnicity of US biobank participants compared to the US Census. J Community Genet (2017) 0.75
Hair Levels of PrEP Drugs Measure Adherence and are Associated with Renal Decline Among Men/Transwomen in an Open Label PrEP Study. AIDS (2017) 0.75
Psychometric evaluation of the Condom Barriers and Motivations Scale (CBMS). J Behav Med (2016) 0.75
Plasma Tenofovir-levels to Support Adherence to TDF/FTC Pre-exposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. J Acquir Immune Defic Syndr (2017) 0.75
Awareness, Willingness, and Use of Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Washington, DC and Miami-Dade County, FL: National HIV Behavioral Surveillance, 2011 and 2014. J Acquir Immune Defic Syndr (2017) 0.75
HIV Preexposure Prophylaxis and Condomless Sex: Disentangling Personal Values From Public Health Priorities. Am J Public Health (2017) 0.75
Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study. Prev Sci (2017) 0.75
Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project. PLoS One (2017) 0.75
Evaluating Testing Strategies for Identifying Youths With HIV Infection and Linking Youths to Biomedical and Other Prevention Services. JAMA Pediatr (2017) 0.75
Challenges in Translating PrEP Interest into Uptake in an Observational Study of Young Black MSM. J Acquir Immune Defic Syndr (2017) 0.75
Context matters: PrEP adherence is associated with sexual behavior among HIV serodiscordant couples in East Africa. J Acquir Immune Defic Syndr (2017) 0.75
Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence. J Int AIDS Soc (2017) 0.75
HIV pre-exposure prophylaxis implementation at local health departments: a statewide assessment of activities and barriers. J Acquir Immune Defic Syndr (2017) 0.75
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad (2017) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis (2014) 5.59
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (2012) 4.26
Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav (2007) 4.07
Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr (2010) 3.58
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr (2015) 2.80
Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. J Acquir Immune Defic Syndr (2010) 2.79
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med (2012) 2.34
Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med (2014) 2.08
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89
Vulnerability and unmet health care needs. The influence of multiple risk factors. J Gen Intern Med (2005) 1.82
Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis (2011) 1.68
Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. Circulation (2013) 1.68
Health literacy explains racial disparities in diabetes medication adherence. J Health Commun (2011) 1.67
Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study. J Acquir Immune Defic Syndr (2012) 1.41
Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS (2012) 1.40
The contexts of adherence for African Americans with high blood pressure. J Adv Nurs (2000) 1.37
Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis (2014) 1.36
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis (2014) 1.28
Differential predictors of medication adherence in HIV: findings from a sample of African American and Caucasian HIV-positive drug-using adults. AIDS Patient Care STDS (2012) 1.16
Polysubstance use and HIV/STD risk behavior among Massachusetts men who have sex with men accessing Department of Public Health mobile van services: implications for intervention development. AIDS Patient Care STDS (2008) 1.16
Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr (2014) 1.05
Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York. AIDS (2014) 1.02
Trust in primary care providers and antiretroviral adherence in an urban HIV clinic. J Health Care Poor Underserved (2012) 1.02
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr (2014) 1.00
Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? BMC Med (2013) 0.96
Medical mistrust is related to lower longitudinal medication adherence among African-American males with HIV. J Health Psychol (2014) 0.96
Will risk compensation accompany pre-exposure prophylaxis for HIV? Virtual Mentor (2014) 0.88
Racial differences in clinical treatment and self-care behaviors of adults with chronic heart failure. J Am Heart Assoc (2015) 0.84
Preexposure prophylaxis for HIV infection. N Engl J Med (2015) 0.82
Diabetes Screening Among Underserved Adults With Severe Mental Illness Who Take Antipsychotic Medications. JAMA Intern Med (2015) 1.39
Analysis of Green Light Committee implementation and acquisition of second-line drug resistance. Clin Infect Dis (2014) 0.84
A Randomized Trial to Test a Peer Mentor Intervention to Improve Outcomes in Persons Hospitalized With HIV Infection. Clin Infect Dis (2016) 0.83
Inflammation as a Mediator of the Association Between Race and Atrial Fibrillation: Results from the Health, Aging, and Body Composition Study. JACC Clin Electrophysiol (2015) 0.82
Genetic Investigation Into the Differential Risk of Atrial Fibrillation Among Black and White Individuals. JAMA Cardiol (2016) 0.79
PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). J Infect Dis (2016) 0.76
The validity of self-reported behaviors: methods for estimating underreporting of risk behaviors. Ann Epidemiol (2016) 0.75
How are transgender women acquiring HIV? Insights from phylogenetic transmission clusters in San Francisco. AIDS (2019) 0.75